Over the years, CZV has achieved a strong technical and scientific structure that has enabled the most demanding challenges in the field of biotechnology to be undertaken.

Thanks to our extensive experience in the animal health sector and our association with high-tech companies, universities and international research centres, our scientific team works on the development of products and innovative solutions for animal health.

The result of this long-term investment is reflected in the development of our latest internationally renowned product line:

SILIRUM^® and GUDAIR^®  for the prevention and control of the paratuberculosis or Johne´s disease. These vaccines are commonly used in Australia, New Zealand, South Africa and numerous European countries too.

RB-51^®  represents vanguard development over the last 50 years in the control and eradication of bovine brucellosis. This enables differentiation between a vaccinated and an infected animal. Thanks to RB-51^® many countries have seen dramatically reduced incidences of brucellosis, while others have already been able to achieve a "brucellosis-free” status.

BLUEVAC^® is our brand name for the inactivated vaccines used against the different serotypes of the bluetongue virus. As a result of the recent pan-European emergence of this disease by request of the Ministry of Agriculture of Spain. CZV has given high priority to the development of these vaccines and has developed the BLUEVAC^® monovalent and bivalent vaccines, against the different serotypes of the bluetongue virus:

• Serotype 1
• Serotype 4
• Serotype 8